Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: bluejeans who wrote (19338)	4/19/1998 5:24:00 PM
From: bluejeans	Read Replies (1) \| Respond to of 32384

possibly off topic<G> this may be the wave of the future here;) Message 4075248

To: bluejeans who wrote (19338)	4/20/1998 9:23:00 AM
From: bluejeans	Read Replies (2) \| Respond to of 32384

Signal Transduction, Part II: Advances in Clinical Development Lucy J. Sannes, Ph.D. Spectrum, Drug Discovery and Design, Issue #9, 7/8/97, 23 pages 97H509 Signal transduction-the process of transmitting a signal across the cell membrane and throughout the cell-is an integral part of normal physiological processes. It can also contribute to many diseases, however, including cancer, inflammation and immune diseases, asthma, allergy, diabetes, cardiovascular diseases, central nervous system (CNS) diseases, and infectious diseases. The receptors found on cell membranes-including G-protein-coupled receptors (GPCRs), growth factor receptors with intrinsic tyrosine kinase activity, and receptors associated with kinases-and other proteins in these pathways represent potential targets for novel therapeutic agents. With the wealth of drug targets and potential disease indications, the field of signal transduction has attracted the attention of many companies, ranging from small start-ups to major pharmaceutical firms. This article profiles some of the leading biopharmaceutical firms working in this area and describes some of the promising compounds and avenues of research that may yield commercial products based on signal transduction technology. Key Words: Allergies, Asthma, Cancer-R&D opportunities, Cancer-therapeutics, Cardiovascular diseases-R&D opportunities, Cardiovascular diseases-therapeutics, Immune disorders, Infectious diseases-R&D opportunities, Inectious diseases- therapeutics, Inflammatory disorders Companies: Ariad Pharmaceuticals, Cadus Pharmaceutical, cti, Isis Pharmaceuticals, Ligand Pharmaceuticals, ProScript, Signal Pharmaceuticals, Sugen, Tularik Has anyone found a full copy of this article? Bob